Oroxat (Roxadustat) is a first-in-class oral HIF-Prolyl Hydroxylase Inhibitor (HIF-PHI) indicated for the treatment of symptomatic anemia associated with Chronic Kidney Disease (CKD). It helps increase hemoglobin levels by stimulating the body's natural production of erythropoietin (EPO) and improving iron utilization.
Indications
- Treatment of symptomatic anemia in adult patients with Chronic Kidney Disease (CKD)
- Suitable for both dialysis-dependent and non-dialysis CKD patients as prescribed by a physician
Pharmacology
Roxadustat works by inhibiting Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH), leading to:
- Increased endogenous erythropoietin (EPO) production
- Enhanced red blood cell formation (erythropoiesis)
- Reduced hepcidin levels
- Improved iron absorption and utilization
- Increased hemoglobin (Hb) levels
- Better management of CKD-related anemia
Dosage & Administration
- Administered orally three times per week
- Should not be taken on consecutive days
- Can be taken with or without food
- Dose should be individualized based on body weight, hemoglobin levels, and clinical response
- Target hemoglobin level: 10-12 g/dL
Drug Interactions
Use with caution alongside:
- Phosphate binders and multivalent cation-containing products (take Oroxat at least 1 hour later)
- Gemfibrozil
- Probenecid
- Statins such as Simvastatin, Rosuvastatin, and Atorvastatin
Side Effects
Common side effects include:
- Hypertension
- Diarrhea
- Nausea
- Peripheral edema
- Hyperkalemia
- Vascular access thrombosis
Precautions & Warnings
- Use cautiously in patients with a history of thrombosis
- Use with caution in patients with seizure disorders
- Not recommended in severe liver impairment
- Avoid use in patients with active serious infections
- Regular monitoring of hemoglobin levels is required
Contraindications
- Pregnancy
- Breastfeeding
- Severe hepatic impairment
- Conditions where treatment risks outweigh benefits as determined by the physician